The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“have shown that DPP4i exhibit cardiovascular neutrality in T2DM patients.”
From The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across the trials of this drug class, there appears to be no interaction by age-group (110-112).”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials-Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (293), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (294), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (295)-did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [294]
The cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials—Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (312), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (313), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (314)—did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [313]
The cited source says what the claim attributes to it.
In the citing paper
“The comparator, sitagliptin, served as a placebo proxy regarding the outcome of interest as it showed no effect on heart failure events in a major randomized clinical trial and previously successfully served as a placebo proxy in claims data analyses.15,18,19”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [19]
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [31]
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“Sitagliptin and linagliptin had a neutral effect.174,[178][179][180]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [215]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“Likewise, sitagliptin in the TECOS trial had no signal of excess rates of HF. 18,185”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“In mice, GLP-1 causes vasodilation through both GLP-1 receptor-dependent and -independent mechanisms.211”
From The Vasculature in Prediabetes (2018) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 628
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Cited by
Sorted by citations
Items 801–900 of 1,006
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes
Libianto, R., Davis, T. M. E., & Ekinci, E. I. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50472 · Cited by 26
Özdemir, S., Baid, D., Verghese, N. R., Lam, A. Y. R., Lee, P. C., Lim, A. Y., Zhu, L., Ganguly, S., Finkelstein, E. A., & Goh, S. (2020) · Value in Health · doi:10.1016/j.jval.2020.01.023 · Cited by 27
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
Filippatos, T. D., Tzavella, E., Rizos, C. V., Elisaf, M., & Liamis, G. L. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361400 · Cited by 27
Report from the 5th cardiovascular outcome trial (CVOT) summit
Schnell, O., Standl, E., Cos, X., Heerspink, H. J. L., Itzhak, B., Lalic, N. M., Nauck, M. A., & Ceriello, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01022-7 · Cited by 26
Self-citationHyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Htoo, P. T., Buse, J. B., Gokhale, M., Marquis, M. A., Pate, V., & Stürmer, T. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2068-3 · Cited by 25
Self-citationChang, C., Chang, Y., Lin, J., Caffrey, J. L., Wu, L., Lai, M., & Chuang, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.125 · Cited by 25
Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease
Yang, G., Li, Y.-Z., Cui, L., Jiang, H., Li, X., Jin, C., Jin, D., Zhao, G., Jin, J., Sun, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163027 · Cited by 25
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
Zonszein, J., & Groop, P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0208-5 · Cited by 25
Diabetes and Hypertension: Clinical Update
Khangura, D., Kurukulasuriya, L. R., Whaley‐Connell, A. T., & Sowers, J. R. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy025 · Cited by 25
Shah, D., Risebrough, N. A., Perdrizet, J. E., Iyer, N. N., Gamble, C. L., & Dang‐Tan, T. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s180067 · Cited by 25
Nauck, M. A., McGuire, D. K., Pieper, K. S., Lokhnygina, Y. V., Strandberg, T. E., Riefflin, A., Delibaşı, T., Peterson, E. D., White, H. D., Scott, R. S., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0921-2 · Cited by 25
Self-citationElif, K., Kocazorbaz, E. K., Moulahoum, H., Alpat, Ş., & Zihnioğlu, F. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13179 · Cited by 25
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 25
Brønden, A., Christensen, M., Glintborg, D., Snorgaard, O., Kofoed‐Enevoldsen, A., Madsen, G. K., Toft, K., Kristensen, J. K., Højlund, K., Hansen, T. K., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15157 · Cited by 27
Yang, T., Liaw, Y., Huang, J., Chang, H., Chang, K.-W., & Ueng, K. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0817-x · Cited by 25
Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 25
Chao, C., Wang, J., Wu, H., Chien, K., & Hung, K. (2017) · Oncotarget · doi:10.18632/oncotarget.18081 · Cited by 26
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.07.011 · Cited by 25
Doğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 27
Ueki, K., Tanizawa, Y., Nakamura, J., Yamada, Y., Inagaki, N., Watada, H., Shimomura, I., Nishimura, R., Miyoshi, H., Abiko, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001787 · Cited by 25
Bae, J. H., Park, E.-G., Kim, S., Kim, S. G., Hahn, S., & Kim, N. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.912 · Cited by 26
Myocardial dysfunction and cardiovascular disease in type 2 diabetes
Ofstad, A. P. (2016) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2016.1155230 · Cited by 25
The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure
Scirica, B. M. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0184 · Cited by 25
Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease
Aguilar, D. A. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003316 · Cited by 25
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Lalic, K. S., Škrha, J., Valensi, P. E., & Ceriello, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0667-2 · Cited by 25
Self-citationCardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Poledniczek, M., Neumayer, C., Kopp, C. W., Schlager, O., Gremmel, T., Józkowicz, A., Gschwandtner, M. E., Koppensteiner, R., & Wadowski, P. P. (2023) · Biomedicines · doi:10.3390/biomedicines11082284 · Cited by 26
Ayoub, M., Aibani, R., Dodd, T. M., Ceesay, M. M., Bhinder, M. M., Faris, C., Amin, N. A., & Daglilar, E. S. (2024) · Cancers · doi:10.3390/cancers16183224 · Cited by 25
Nagamine, A., Hasegawa, H., Hashimoto, N., Yamada-Inagawa, T., Hirose, M., Kobara, Y., Tadokoro, H., Kobayashi, Y., & Takano, H. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.12.003 · Cited by 24
Guzauskas, G. F., Rind, D. M., Fazioli, K., Chapman, R. H., Pearson, S. D., & Hansen, R. N. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.4.455 · Cited by 25
Liao, J., Kang, A., Xia, C., Young, T. K., Tanna, G. L. D., Arnott, C. G., Pollock, C. A., Krishnan, A. V., Agarwal, R., Bakris, G. L., et al. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101331 · Cited by 24
Meling, S., Tjora, E., Eichele, H., Ejskjær, N., Carlsen, S., Njølstad, P. R., Brock, C., & Søfteland, E. W. (2023) · Journal of Diabetes Research · doi:10.1155/2023/4441115 · Cited by 24
Tan, L., Wang, Z., Okoth, K., Toulis, K. A., Denniston, A. K., Singh, B. M., Crowe, F. L., Sainsbury, C. A. R., Wang, J., & Nirantharakumar, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1303238 · Cited by 25
Oral Hypoglycaemic Agents: Non-Insulin Medications for Type 2 Diabetes Patients
Mohajan, D., & Mohajan, H. K. (2024) · Innovation in Science and Technology · doi:10.56397/ist.2024.01.04 · Cited by 24
Brenner, C., Adrion, C., Grabmaier, U., Theisen, D., von Ziegler, F., Leber, A. W., Becker, A., Sohn, H., Hoffmann, E., Mansmann, U., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.180 · Cited by 24
Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.354 · Cited by 24
Huang, C., Wang, W., Sung, S., Chen, C., Lip, G. Y. H., Cheng, H., & Chiang, C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13342 · Cited by 24
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 26
Zhang, X., Shao, F., Zhu, L., Ze, Y., Zhu, D., & Bi, Y. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0246-x · Cited by 26
Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy
Volpe, M., Societies, O. B. O. T. S., Battistoni, A., Gallo, G., Rubattu, S. D., & Tocci, G. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0278-8 · Cited by 24
Advances in the management of diabetes: therapies for type 2 diabetes
Tsoutsouki, J., Wunna, W., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137404 · Cited by 24
Zhang, F., Xu, S., Tang, L., Pan, X., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00288 · Cited by 24
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 23
Barnett, A. H., Charbonnel, B. H., Moses, R. G., & Kalra, S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1081589 · Cited by 23
Chen, H., Zhou, X., Chen, T., Liu, B., Jin, W., Gu, H., Hong, T., & Zhang, G. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0198-3 · Cited by 23
Yang, Y., Kornelius, E., Chiou, J., Lai, Y., Lo, S., Peng, C., & Huang, C. (2017) · Journal of Women s Health · doi:10.1089/jwh.2016.6040 · Cited by 23
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 23
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 23
Funamizu, T., Iwata, H., Nishida, Y., Miyosawa, K., Doi, S., Chikata, Y., Shitara, J., Endo, H., Wada, H., Naito, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-00996-8 · Cited by 23
Cardiovascular Risk Factors: It's Time to Focus on Variability!
Barnett, M. P., & Bangalore, S. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.2.255 · Cited by 23
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14055 · Cited by 23
Davies, M. J., Bianchi, C., & Prato, S. D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 24
Rai, A. K., Lee, B., Gomez, R., Rajendran, D., Khan, M., & Garikipati, V. N. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612722 · Cited by 23
Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 23
Jones, L., & Jones, A. M. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1029 · Cited by 23
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 23
Patel, P. A., Liang, L., Khazanie, P., Hammill, B. G., Fonarow, G. C., Yancy, C. W., Bhatt, D. L., Curtis, L. H., & Hernandez, A. F. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002638 · Cited by 23
Risk assessment and management of post-transplant diabetes mellitus
Han, E., Kim, M. S., Kim, Y. S., & Kang, E. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.07.011 · Cited by 24
Omarigliptin for the treatment of type 2 diabetes mellitus
Evans, P. M. S., & Bain, S. C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218472 · Cited by 23
Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Mosenzon, O., Pollack, R. M., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3003 · Cited by 24
Kuramitsu, S., Miyauchi, K., Yokoi, H., Suwa, S., Nishizaki, Y., Yokoyama, T., Nojiri, S., Iwabuchi, M., Shirai, S., Andò, K., et al. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.08.011 · Cited by 23
Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Tarquini, R., Pala, L., Brancati, S., Vannini, G., Cosmo, S. D., Mazzoccoli, G., & Rotella, C. M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170705111356 · Cited by 23
Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine
Valencia, W. M., Botros, D., Vera-Nunez, M. A., & Dang, S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1052-y · Cited by 26
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 23
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
Ikeda, M., & Shimazawa, R. (2019) · Journal of General and Family Medicine · doi:10.1002/jgf2.244 · Cited by 24
Darsalia, V., Johansen, O. E., Lietzau, G., Nyström, T., Klein, T., & Patrone, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00493 · Cited by 23
Yamada, T., Iwasaki, K., Maedera, S., Ito, K., Takeshima, T., Noma, H., & Shojima, N. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1706043 · Cited by 23
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 25
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Tadić, M., Sala, C., Saeed, S., Grassi, G. M., Mancia, G., Rottbauer, W., & Cuspidi, C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10106-9 · Cited by 23
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 28
Sportiello, L., Rafaniello, C., Scavone, C., Vitale, C., Rossi, F., & Capuano, A. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.002 · Cited by 25
on behalf of the Sitagliptin Registry Kinki Cardiologists’ Study (SIRKAS) Investigators, Nakamura, T., Iwanaga, Y., Miyaji, Y., Nohara, R., Ishimura, T., & Miyazaki, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0371-z · Cited by 22
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
Thompson, P. L., & Davis, T. M. E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.10.008 · Cited by 23
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24
Inagaki, N., Yang, W., Watada, H., Ji, L., Schnaidt, S., Pfarr, E., Okamura, T., Johansen, O. E., George, J. T., von Eynatten, M., et al. (2019) · Diabetology International · doi:10.1007/s13340-019-00412-x · Cited by 22
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate
Charoo, N. A., Abdallah, D. B., Abdelgader, A., Haque, K. U., Hassan, H. A., Abrahamsson, B., Cristofoletti, R., Langguth, P., Mehta, M., Parr, A. F., et al. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.09.031 · Cited by 22
González‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 22
Tufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 22
Richardson, T. L., Halvorson, A. E., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T. A., & Roumie, C. L. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2751 · Cited by 22
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 22
McCoy, R. G., SWARNA, K. S., Deng, Y., Herrin, J. S., Ross, J. S., Kent, D. M., Borah, B. J., Crown, W. H., Montori, V. M., Umpierrez, G. E., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100852 · Cited by 22
Newer antidiabetic drugs and calorie restriction mimicry
Jacob, J., Kalra, S., & Gupta, Y. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.172242 · Cited by 22
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
Kankanala, S., Syed, R. M., Gong, Q., Ren, B., Rao, X., & Zhong, J. (2016) · PubMed Central · Cited by 22
White, W. B., Wilson, C., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Heller, S. K., Mehta, C. R., Nissen, S. E., Zannad, F. M., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07797 · Cited by 22
Rahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 23
Lüscher, T. F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw566 · Cited by 22
Lullo, L. D., Mangano, M., Ronco, C., Bàrbera, V., Pascalis, A. D., Bellasi, A., Russo, D., Iorio, B. R. D., & Cozzolino, M. G. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.005 · Cited by 24
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 22
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
Verbrugge, F. H. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0340-1 · Cited by 22
Suda, M., Shimizu, I., Yoshida, Y., Hayashi, Y., Ikegami, R., Katsuumi, G., Wakasugi, T., Yoshida, Y., Okuda, S., Soga, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182422 · Cited by 22
dʼEmden, M. C., Amerena, J. V., Deed, G., Pollock, C. A., & Cooper, M. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.023 · Cited by 22
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Menon, V., Lincoff, A. M., Nicholls, S. J., Jasper, S. E., Wolski, K., McGuire, D. K., Mehta, C. R., Rosenstock, J., Lopez, C. M., MARCINAK, J. F., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0755 · Cited by 24
Self-citationNova abordagem para o tratamento da diabetes: da glicemia à doença cardiovascular
Aguíar, C., Duarte, R., & Carvalho, D. M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2018.03.013 · Cited by 22
Li, G., Crowley, M. J., Tang, H., Yang, J. Y., Sandler, R. S., & Wang, T. (2019) · Diabetes Care · doi:10.2337/dc18-1578 · Cited by 22
Martínez, J. J. G., Malkin, S. J. P., Martín, V., Hallén, N., & Hunt, B. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1681436 · Cited by 22
Antidiabetic drugs and blood pressure changes
Ilias, Ι., Thomopoulos, C., Michalopoulou, H., Bazoukis, G., Tsioufis, C. P., & Makris, T. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105108 · Cited by 22
On restricted mean time in favor of treatment
Mao, L. (2021) · Biometrics · doi:10.1111/biom.13570 · Cited by 22
Metadata
- Authors
- Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Oxford (GB)
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Duke University (US)
- St. Michael's Hospital (CA)
- George Washington University (US)
- The University of Texas Southwestern Medical Center (US)
- Helmholtz Munich (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 232-242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142830692
- Semantic Scholar
- 5f5aabad35a6c6137b19d8640d5d6cafc91815e5
- Cited by
- 2,577
- References
- 16
- Citations by year
- 2026: 68 · 2025: 121 · 2024: 120 · 2023: 139 · 2022: 170 · 2021: 210 · 2020: 289 · 2019: 267 · 2018: 343 · 2017: 343 · 2016: 378 · 2015: 120
- FWCI
- 341.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (acceptedVersion, cc-by-nc-nd)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- South Australian Health and Medical Research Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- sitagliptin, type 2 diabetes, cardiovascular disease, DPP-4 inhibitors, major adverse cardiovascular events, heart failure hospitalization, acute pancreatitis, pancreatic cancer, HbA1c, glycemic control, non-inferiority
- MeSH terms
- Sitagliptin Phosphate, Administration, Oral, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Follow-Up Studies, Heart Diseases, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemic Agents, Pyrazines, Triazoles, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
